Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.65 CHF | -0.26% | +8.50% | +6.66% |
Sales 2024 * | 180M 199M | Sales 2025 * | 205M 226M | Capitalization | 453M 500M |
---|---|---|---|---|---|
Net income 2024 * | 20M 22.06M | Net income 2025 * | 36M 39.71M | EV / Sales 2024 * | 2.83 x |
Net Debt 2024 * | 57.88M 63.85M | Net Debt 2025 * | 12.51M 13.8M | EV / Sales 2025 * | 2.28 x |
P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
13.7
x | Employees | 147 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.55% |
Latest transcript on Basilea Pharmaceutica AG
1 day | -0.40% | ||
1 week | +5.62% | ||
Current month | +6.97% | ||
1 month | +4.74% | ||
3 months | +4.16% | ||
6 months | -8.40% | ||
Current year | +6.52% |
Managers | Title | Age | Since |
---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 59 | 14-08-31 |
Adesh Kaul
DFI | Director of Finance/CFO | 50 | 08-12-31 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nicole Onetto
BRD | Director/Board Member | 71 | 17-04-26 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 21-12-31 |
Director/Board Member | 69 | 13-04-08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 735 M€ | -.--% | - | |
0.00% | 10 M€ | -3.35% | - | |
0.00% | 36 M€ | +4.74% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 37.65 | -0.26% | 22 578 |
24-03-27 | 37.75 | +0.67% | 28,753 |
24-03-26 | 37.5 | +1.63% | 22,909 |
24-03-25 | 36.9 | +0.14% | 20,891 |
24-03-22 | 36.85 | +3.51% | 41,895 |
Delayed Quote Swiss Exchange, March 28, 2024 at 05:48 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.52% | 500M | |
+9.16% | 45.97B | |
+53.63% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |